INVO Fertility, Inc.
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body… Read more
INVO Fertility, Inc. (IVF) - Net Assets
Latest net assets as of September 2025: $5.85 Million USD
Based on the latest financial reports, INVO Fertility, Inc. (IVF) has net assets worth $5.85 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.83 Million) and total liabilities ($12.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.85 Million |
| % of Total Assets | 31.06% |
| Annual Growth Rate | 38.23% |
| 5-Year Change | 121.96% |
| 10-Year Change | N/A |
| Growth Volatility | 656.31 |
INVO Fertility, Inc. - Net Assets Trend (2006–2024)
This chart illustrates how INVO Fertility, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INVO Fertility, Inc. (2006–2024)
The table below shows the annual net assets of INVO Fertility, Inc. from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.75 Million | +1328.13% |
| 2023-12-31 | $892.60K | +191.30% |
| 2022-12-31 | $-977.61K | -113.37% |
| 2021-12-31 | $7.31 Million | +27.29% |
| 2020-12-31 | $5.74 Million | +254.65% |
| 2019-12-31 | $-3.71 Million | -36.32% |
| 2018-12-31 | $-2.72 Million | +45.43% |
| 2017-12-31 | $-4.99 Million | -8.11% |
| 2016-12-31 | $-4.62 Million | -22.91% |
| 2015-12-31 | $-3.76 Million | +13.81% |
| 2014-12-31 | $-4.36 Million | -14.26% |
| 2013-12-31 | $-3.81 Million | -13.11% |
| 2012-12-31 | $-3.37 Million | -15.30% |
| 2011-12-31 | $-2.93 Million | -17.86% |
| 2010-12-31 | $-2.48 Million | +19.47% |
| 2009-12-31 | $-3.08 Million | -1260.36% |
| 2008-12-31 | $-226.57K | -124.49% |
| 2007-12-31 | $-100.93K | -368.86% |
| 2006-12-31 | $37.54K | -- |
Equity Component Analysis
This analysis shows how different components contribute to INVO Fertility, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6715643200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00 | 0.00% |
| Other Components | $79.91 Million | 626.89% |
| Total Equity | $12.75 Million | 100.00% |
INVO Fertility, Inc. Competitors by Market Cap
The table below lists competitors of INVO Fertility, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EVERYBODY LOVES LANGUAGES
F:VB6
|
$1.27 Million |
|
Birdie Win Corporation
PINK:BRWC
|
$1.27 Million |
|
ELIA SYSTEM OP.
MU:E4S
|
$1.27 Million |
|
Golden Goliath Resources Ltd
PINK:GGTHF
|
$1.27 Million |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
$1.27 Million |
|
Prosper Engineering Public Company Limited
BK:PROS
|
$1.27 Million |
|
Knusford Bhd
KLSE:5035
|
$1.27 Million |
|
ESGL Holdings Limited Warrants
NASDAQ:ESGLW
|
$1.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INVO Fertility, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 892,825 to 12,747,473, a change of 11,854,648 (1327.8%).
- Net loss of 9,095,838 reduced equity.
- New share issuances of 1,809,035 increased equity.
- Other factors increased equity by 19,141,451.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.10 Million | -71.35% |
| Share Issuances | $1.81 Million | +14.19% |
| Other Changes | $19.14 Million | +150.16% |
| Total Change | $- | 1327.77% |
Book Value vs Market Value Analysis
This analysis compares INVO Fertility, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.53x to 0.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.16 | $0.74 | x |
| 2007-12-31 | $-46.78 | $0.74 | x |
| 2008-12-31 | $-0.99 | $0.74 | x |
| 2009-12-31 | $-9.01 | $0.74 | x |
| 2010-12-31 | $-6.25 | $0.74 | x |
| 2011-12-31 | $-270.43 | $0.74 | x |
| 2012-12-31 | $-311.80 | $0.74 | x |
| 2013-12-31 | $-352.67 | $0.74 | x |
| 2014-12-31 | $-402.97 | $0.74 | x |
| 2015-12-31 | $-4.68 | $0.74 | x |
| 2016-12-31 | $-5.31 | $0.74 | x |
| 2017-12-31 | $-5.65 | $0.74 | x |
| 2018-12-31 | $-2.96 | $0.74 | x |
| 2019-12-31 | $-3.82 | $0.74 | x |
| 2020-12-31 | $5.23 | $0.74 | x |
| 2021-12-31 | $3.44 | $0.74 | x |
| 2022-12-31 | $-0.40 | $0.74 | x |
| 2023-12-31 | $0.29 | $0.74 | x |
| 2024-12-31 | $41.18 | $0.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INVO Fertility, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.25%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 3.64x
- Recent ROE (-71.35%) is below the historical average (-64.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -19.68% | 0.00% | 0.00x | 1.01x | $-11.14K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-204.00K |
| 2008 | 0.00% | -4930.66% | 0.05x | 0.00x | $-1.85 Million |
| 2009 | 0.00% | -7375.39% | 0.14x | 0.00x | $-4.35 Million |
| 2010 | 0.00% | -226.81% | 0.37x | 0.00x | $94.76K |
| 2011 | 0.00% | -1115.30% | 0.56x | 0.00x | $-504.94K |
| 2012 | 0.00% | -1182.14% | 0.45x | 0.00x | $-329.18K |
| 2013 | 0.00% | -2810.77% | 0.22x | 0.00x | $-379.20K |
| 2014 | 0.00% | -10444.13% | 0.15x | 0.00x | $-1.30 Million |
| 2015 | 0.00% | -42426.61% | 0.02x | 0.00x | $-4.58 Million |
| 2016 | 0.00% | -4173.30% | 0.18x | 0.00x | $-1.66 Million |
| 2017 | 0.00% | -248.87% | 1.06x | 0.00x | $-202.95K |
| 2018 | 0.00% | -622.22% | 0.64x | 0.00x | $-2.80 Million |
| 2019 | 0.00% | -146.43% | 0.82x | 0.00x | $-1.80 Million |
| 2020 | -145.34% | -804.73% | 0.09x | 1.91x | $-8.92 Million |
| 2021 | -91.03% | -159.97% | 0.40x | 1.43x | $-7.39 Million |
| 2022 | 0.00% | -1324.81% | 0.22x | 0.00x | $-10.79 Million |
| 2023 | -899.91% | -266.00% | 0.16x | 20.73x | $-8.12 Million |
| 2024 | -71.35% | -139.25% | 0.14x | 3.64x | $-10.37 Million |
Industry Comparison
This section compares INVO Fertility, Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INVO Fertility, Inc. (IVF) | $5.85 Million | -19.68% | 2.22x | $1.27 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |